pharmaphorum

JUNE 27, 2022

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. The post Ipsen beefs up in oncology, buying US biopharma Epizyme appeared first on.

Biopharma 111

Biopharma Sales Prescription FDA 111

European Pharmaceutical Review

JANUARY 23, 2025

1 all revenue in big pharma now come from dealmaking, confirming a need for robust inorganic growth and value creation strategies The year began with this forecast holding true, as the pharmaceutical industry declared major M&A deals including Johnson & Johnsons acquisition of Intra-Cellular Therapies, Inc. trillion Firepower.

Pharma 59

Pharma Food and Drug Administration Pharmaceutical Government 59

European Pharmaceutical Review

NOVEMBER 30, 2023

For example, the GMP report stated that the contract development and manufacturing organisation (CDMO) eXmoor pharma, will be launching a cell and gene therapy process development and clinical manufacturing facility in Bristol. Licensing of the manufacturing suites is expected in early 2024.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97

Pharmaceutical Representative Training

JANUARY 29, 2025

Newer or less prominent manufacturers will struggle the most with these challenges, but there are teams with the experience and tools to overcome these obstacles and get more biosimilars into the pharma market. link] The post Biosimilars: The Future of Affordable Biologic Therapies appeared first on Pharma Sales Training.

Marketing 52

Marketing Healthcare Healthcare Physicians 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Clarivate

MAY 13, 2024

In March 2024, New York received approval for a five-year Medicaid expansion through April 1, 2028, extending eligibility to include individuals with incomes up to 250% of the federal poverty level (eligibility was previously capped at 200%).

Insurance 52

Insurance Marketing Healthcare Healthcare 52

Clarivate

MAY 31, 2023

A glance at the 2022 top selling drugs for the biggest pharma companies reveals how dependent many large pharmas are on a small basket of products – most acquired through partnerships or acquisitions – that are nearing loss of exclusivity. Pharma is placing bigger bets on a smaller number of therapeutics and technology platforms.

Pharma 52

Pharma Biopharma Medicine Healthcare 52